Science News
Discover the news and inspiring materials from the world of biotechnology.

Popular obesity drug cuts the risk of heart attacks and strokes
Semaglutide (Ozempic) has been found to reduce the risk of cardiovascular events in obese people.
Learn more
FDA approves first ustekinumab biosimilar
FDA approves first ustekinumab biosimilar Ustekinumab (Stelara®), a blockbuster monoclonal antibody originally developed by Janssen Pharmaceuticals, has just got a biosimilar counterpart. The new biosimilar, Wezlana®, manufactured by Amgen, received FDA approval in all indications of the originator, which include plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. The FDA also granted it an […]
Learn more
Another win for antibody-drug conjugates in breast cancer
Sacituzumab govitecan, an antibody-drug conjugate targeting Trop-2 antigen, was reported to increase survival in HR-positive, EGFR2-negative breast cancer.
Learn more
Updated Novavax’s COVID vaccine effectively neutralizes…
Novavax’s vaccine for 2023-24 season induced neutralizing responses against newly emerging subvariants EG.5.1 and XBB.1.16.6. in in vivo models.
Learn more
Market welcomes the arrival of new RSV vaccines
The FDA has approved novel vaccines preventing the grave complications of RSV infection.
Learn more
Mabion purchase of new Cytiva Xcellerex™ XDR bioreactors
Mabion signs contract to purchase new bioreactors diversifies technology and opens to new customers.
Learn more